RecruitingNot ApplicableNCT06067100

U-LABA/ICS Effects on Exercise Performance, Indacaterol

Physiological Response to U-LABA/ICS With Emphasis on Exercise Performance, Indacaterol


Sponsor

Morten Hostrup, PhD

Enrollment

30 participants

Start Date

Jan 15, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of the project is to investigate exercise performance in humans following bronchodilation induced by acute inhalation of beta2-agonist indacaterol + mometasonefuroate


Eligibility

Min Age: 18 YearsMax Age: 39 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Indacaterol and Mometasonefluroate (high dose), a drug called Indacaterol and Mometasonefluroate (low dose), and others for people with exercise performance. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 39 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGIndacaterol and Mometasonefluroate (low dose)

Participants are administered 125 µg indacaterol + mometasonefluroate

DRUGPlacebo

Participants are administered placebo

DRUGIndacaterol and Mometasonefluroate (high dose)

Participants are administered 500 µg indacaterol + mometasonefluroate


Locations(1)

August Krogh Building

Copenhagen, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06067100


Related Trials